Angita Pharmaceuticals and Motac enter into a joint research collaboration to evaluate AG-0029, a putative treatment for both the motor and cognitive symptoms in Parkinson’s disease.
AG-0029, a combined dopamine D2 receptor agonist and histamine H3 receptor antagonist, was discovered by Angita and has been shown to have cognitive enhancing potential and PD-related motor improvements in rodent models. Motac will invest in the project to extend the existing proof-of-concept studies including evaluation of Parkinson’s disease-related motor and cognitive disturbances in the most relevant and translational models. Jointly, Angita and Motac aim to ensure the continued development of AG-0029, raising funds to initiate additional non-clinical development studies.
About Angita Pharmaceuticals
Angita is a virtual drug discovery company with a pipeline of innovative new chemical entities addressing unmet clinical needs. We collaborate with academic institutes and early spin-outs applying our discovery expertise with the goal of partnering, out-licensing or spinning-out drug development candidates at pre-clinical development stage.
Motac is a preclinical research company dedicated to working with pharmaceutical and biotechnology companies that are developing new treatments for diseases of the central nervous system. As a company, we have unparalleled expertise in the fields of movement disorders, such as Parkinson’s disease and dyskinesias, and in the fields of neuropsychology and cognition.